Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2015 ◽
Vol 33
(15_suppl)
◽
pp. TPS5608-TPS5608
◽
Keyword(s):
Phase Ii
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 5585-5585
◽
2019 ◽
Vol 152
(3)
◽
pp. 548-553
◽